Ignite Creation Date:
2024-05-05 @ 11:35 AM
Last Modification Date:
2024-10-26 @ 9:10 AM
Study NCT ID:
NCT00088192
Status:
COMPLETED
Last Update Posted:
2005-08-30
First Post:
2004-07-21
Brief Title:
Intravitreous Pegaptanib Sodium Injection in Patients With Exudative Age-Related Macular Degeneration AMD
Sponsor:
Eyetech Pharmaceuticals
Organization:
Eyetech Pharmaceuticals
Study Overview
Official Title:
An Open Label Non-Comparative Protocol for Use of Intravitreous Pegaptanib Sodium Injection Every 6 Weeks in Patients With Exudative Age-Related Macular Degeneration AMD
Status:
COMPLETED
Status Verified Date:
2005-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To provide Pegaptanib sodium injection to patients with subfoveal choroidal neovascularization CNV secondary to AMD who are unable to participate in any of the Sponsors other clinical studies with this drug for AMD until such time as the patients lesion is considered to have resolved or stabilized in the opinion of the treating ophthalmologist or product becomes commercially available
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None